Table 7. . Scenario analyses results (RIS-GR vs ALN). Time horizon: 5 years.
| Scenario | Treatment | Cost per patient | QALYs per patient | Fractures | Cost per QALY gained | Cost per Fracture avoided |
|---|---|---|---|---|---|---|
| Gradual loss of treatment effect at years 4 and 5, after treatment for 3 years | RIS-GR ALN |
2829 € 4799 € |
3.7631 3.7513 |
361 439 |
Risedronate GR is the dominant treatment† | Risedronate GR is the dominant treatment† |
| Incidence of fractures with RIS-GR and ALN (-20%) | RIS-GR ALN |
2379 € 4254 € |
3.7885 3.7790 |
290 353 |
Risedronate GR is the dominant treatment† | Risedronate GR is the dominant treatment† |
| Incidence of fractures with RIS-GR and ALN (+20%) | RIS-GR ALN |
3235 € 5291 € |
3.7398 3.7257 |
431 526 |
Risedronate GR is the dominant treatment† | Risedronate GR is the dominant treatment† |
| Unit cost of bone fractures (-20%) | RIS-GR ALN |
2301 € 4158 € |
3.7611 3.7493 |
360 439 |
Risedronate GR is the dominant treatment† | Risedronate GR is the dominant treatment† |
| Unit cost of bone fractures (+20%) | RIS-GR ALN |
2376 € 4250 € |
3.7724 3.7606 |
362 441 |
Risedronate GR is the dominant treatment† | Risedronate GR is the dominant treatment† |
| Utilities with bone fractures (-20%) | RIS-GR ALN |
3296 € 5366 € |
3.7601 3.7483 |
360 439 |
Risedronate GR is the dominant treatment† | Risedronate GR is the dominant treatment† |
| Utilities with bone fractures (+20%) | RIS-GR ALN |
2864 € 4843 € |
3.8143 3.8123 |
362 440 |
Risedronate GR is the dominant treatment† | Risedronate GR is the dominant treatment† |
| Patients <65 years of age | RIS-GR ALN |
1270 € 2715 € |
3.8011 3.8005 |
139 143 |
Risedronate GR is the dominant treatment† | Risedronate GR is the dominant treatment† |
| Patients ≥65 years of age | RIS-GR ALN |
2805 € 5167 € |
3.7710 3.7514 |
345 475 |
Risedronate GR is the dominant treatment† | Risedronate GR is the dominant treatment† |
| Annual discount cost and benefits: 3% | RIS-GR ALN |
2530 € 4345 € |
3.4456 3.4351 |
324 394 |
Risedronate GR is the dominant treatment† | Risedronate GR is the dominant treatment† |
†
With weekly risedronate GR, fractures are avoided or QALYs are gained, with lower costs per patient, than with weekly Alendronate.
ALN: Weekly Alendronate 70 mg tablets; RIS-GR: Weekly risedronate 35 mg gastro-resistant tablets.